Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system

Hypertension

Volumn 64, Issue 3, 2014, Pages 565-572

  Papademetriou, Vasilios ^a,b,g   Tsioufis, Costas P ^b   Sinhal, Ajay ^c   Chew, Derek P ^c   Meredith, Ian T ^d   Malaiapan, Yuvi ^d   Worthley, Matthew I ^e   Worthley, Stephen G ^f  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c FLINDERS UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ambulatory blood pressure; Home blood pressure; Multielectrode; Renal denervation; Resistant hypertension

Indexed keywords

ABLATION CATHETER; ADULT; ADVERSE OUTCOME; ARTERIAL STENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; FEMALE; FIRST IN HUMAN STUDY; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; KIDNEY FUNCTION; MALE; MULTIELECTRODE ABLATION CATHETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ARTERY; RESISTANT HYPERTENSION; TREATMENT OUTCOME;

AMBULATORY BLOOD PRESSURE; HOME BLOOD PRESSURE; MULTIELECTRODE; RENAL DENERVATION; RESISTANT HYPERTENSION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; DENERVATION; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907598102     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03605     Document Type: Article

References (39)

1. Bradford JR. The innervation of the renal blood vessels. J Physiol. 1889; 10: 358-407.
2. Weiss E. Recent advances in the pathogenesis and treatment of hypertension, a review. Psychosom Med. 1939; 1:180-198.
3. Sen SK. Some observations on decapsulation and denervation of the kidney. Brit J Urol. 1936; 8:319-328.
4. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest. 1935;14:27-30.
5. Page IH, Heuer GJ. The effect of renal denervation on patients suffering from nephritis. J Clin Invest. 1935;14:443-458.
6. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc. 1953;152:1501-1504.
7. Peet MM, Woods WW, Braden S. The surgical treatment of hypertension. JAMA. 1940; 115:1875-1885.
8. DiBona GF, Esler M. Translational medicine: The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245-R253.
9. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: A human postmortem histologic study. Clin Anat. 2012;25:628-633.
10. Doumas M, Douma S. Renal sympathetic denervation: The jury is still out. Lancet. 2010;376:1878-1880.
11. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
12. De la Sierra A, Segura J, Banegas JR, Gorostidi M, De la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57:898-902.
13. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
14. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010; 376:1903-1909.
15. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Śliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-565.
16. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
17. Ormiston JA, Watson T, van Pelt N, Stewart R, Stewart JT, White JM, Doughty RN, Stewart F, Macdonald R, Webster MW. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial. EuroIntervention. 2013;9:70-74.
18. Mahfoud F, Ukena C, Schmieder R, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension: Clinical perspective. Circulation. 2013; 128:132-140.
19. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-1490.
20. Persu A, Jin Y, Azizi M, et al; European Network COordinating research on Renal Denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-156.
21. Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014;129:1440-1451.
22. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
23. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: The EnligHTN I trial. Eur Heart J. 2013;34:2132-2140.
24. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694-2695.
25. Kostka-Jeziorny K, Radziemski A, Tykarski A, Grajek S. Transient renal artery stenosis during renal sympathetic denervation in a patient with resistant hypertension. Kardiol Pol. 2013;71:776.
26. Tsioufis C, Papademetriou V, Dimitriadis K, Tsiachris D, Thomopoulos C, Park E, Hata C, Papalois A, Stefanadis C. Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. Int J Cardiol. 2013;168:987-992.
27. Böhm M, Linz D, Urban D, Mahfoud F, Ukena C. Renal sympathetic denervation: Applications in hypertension and beyond. Nat Rev Cardiol. 2013;10:465-476.
28. Fu Z, Xue H, Guo J, Chen L, Dong W, Gai L, Liu H, Sun Z, Chen Y. Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovasc Diabetol. 2013;12:157.
29. Yamamoto T, Shimano M, Inden Y, Miyata S, Inoue Y, Yoshida N, Tsuji Y, Hirai M, Murohara T. Cystatin C as a predictor of mortality and cardiovascular morbidity after cardiac resynchronization therapy. Circ J. 2013;77:2751-2756.
30. Katholi RE, Winternitz SR, Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest. 1982;69:55-62.
31. Wang L, Lu CZ, Zhang X, Luo D, Zhao B, Yu X, Xia DS, Chen X, Zhao XD. [The effect of catheter based renal synthetic denervation on reninangiotensin- Aldosterone system in patients with resistant hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:3-7.
32. Kaplan NM. Morning surge in blood pressure. Circulation. 2003; 107:1347.
33. Head GA, Lukoshkova EV. Understanding the morning rise in blood pressure. Clin Exp Pharmacol Physiol. 2008;35:516-521.
34. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Śliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-565.
35. Parati G, Ochoa JE, Bilo G. Renal sympathetic denervation and daily life blood pressure in resistant hypertension: simplicity or complexity? Circulation. 2013;128:315-317.
36. Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG. Changes in home versus clinic blood pressure with antihypertensive treatments: A meta-analysis. Hypertension. 2008;52:856-864.
37. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4, 121 patients with focus on trial design: The CONVERGE report. Heart. 2013;99:1579-1587.
38. Elmula EM, Elmula F, Hoffman P, Larstop AC, Fossum E, Brekke M, Kjeldsen SE, Gjonness E, Hjomholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Hoieggen A. Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-resistant Hypertension. Hypertension. 2014; 63: 991-999.
39. Papademetriou V, Tsioufis C, Stefanadis C. Impressive blood pressure and heart rate response after percutaneous renal denervation in a woman with morbid obesity and severe drug-resistant hypertension. J Clin Hypertens (Greenwich). 2013;15:852-855.